Willis C. Lee
CEO, Director · Emmaus Life Sciences, Inc.
IndividualBuying only
- 2026
- Sep 2, 2026
- 1
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Willis C. Lee's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Forbion Growth Opportunities Fund III Cooperatief U.A. - $64.80M in BRVE purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $63.45M in SEPN purchases and sales in the last 12 months
- BVF PARTNERS L P - $62.96M in MLTX purchases and sales in the last 12 months
- Mario Schlosser - $62.90M in OSCR purchases and sales in the last 12 months
- BROADWOOD PARTNERS, L.P. - $62.75M in STAA purchases and sales in the last 12 months
- Jonathan M. Rothberg - $62.19M in BFLY purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Willis C. Lee?
Willis C. Lee is a corporate insider, tracked as CEO, Director of Emmaus Life Sciences, Inc. (EMMA). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Willis C. Lee submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Willis C. Lee been buying or selling stock?
Recorded transactions: 6 open-market purchases ($18K) and 0 open-market sales across all tracked filings.
